July 13, 2005
US appeals court upholds patent for Lilly PMS drug
WASHINGTON (Reuters) - A U.S. appeals court on Wednesday
upheld Eli Lilly and Co.'s patent for its premenstrual drug
Sarafem, rejecting a challenge from generic drugmaker Teva
Pharmaceutical Industries Ltd .
Teva had argued the patent, which covers the use of
fluoxetine to treat premenstrual syndrome (PMS), was invalid
because it was for something that was "obvious."
a lower court ruling that found Teva had infringed the patent.